Deutsche Bank raised the firm’s price target on HCA Healthcare to $359 from $330 and keeps a Buy rating on the shares. The firm says that with the stock trading at 9.1-times consensus 2025 enterprise value to EBITDA, it has received an “unprecedented number of inbounds from clients” trying to figure out what they should do with HCA at these levels.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- Augmedix upgraded to Outperform from In Line at Evercore ISI
- Augmedix price target lowered to $5 from $6.50 at Maxim
- Barclays starts health care facilities, managed care group with Neutral view
- HCA Healthcare initiated with an Overweight at Barclays
- HCA Healthcare Launches Incentive Program for Executives
